Abstract
Background
Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3–4 million new infections and 350 000 deaths occurring each year because of HCV-related complications.
Aim of the work
to determine the efficacy of Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy in NS5A inhibitors (Sofosbuvir & Daclatasvir) resistant patients infected with chronic hepatitis C virus.
Patients and Methods
An observational cross-sectional study was carried out on 20 chronic hepatitis C virus infected patients in The centre of HCV treatment at El Quabary specialized centers in Alexandria where large number of patients receiving their HCV treatment.
Results
all patients (20/20) achieved sustained virological response after 3 months of the last dose of treatment (SVR12).
Conclusion
the new retreatment strategy composed of the triple therapy Qurevo (Ombitasvir/Paritaprevir/Ritonavir)/Sofosbuvir/Ribavirin is effective in the treatment of chronic HCV infected patients previously treated with Sofosbuvir/Daclatasvir/Ribavirin for 12 weeks without achieving sustained virological response (Ns5a inhibitors resistant chronic HCV patients).
PGI2 CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY REFERENCE HOSPITAL DAS CLÍNICAS—UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE (HC-FMUSP)
